Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories
-
Companies with NDRs 6/07
-
Pacific Biosciences (PACB) Stock Explodes 21% As SoftBank Invests $900 Million, Analysts Positive
-
Pacific Biosciences of California (PACB) PT Raised to $45 at Cantor Fitzgerald
-
Pacific Bio (PACB) Prices 19.43M Share Common Offering at $4.47/Sh
-
Pacific Biosciences of California, Inc. Announces Pricing of Public Offering of Common Stock
-
Pacific Biosciences of California, Inc. Announces Pricing of Public Offering of Common Stock
-
Pacific Bio (PACB) Announces $75M Proposed Public Offering of Common Stock
-
Pacific Biosciences of California, Inc. Announces Proposed Public Offering of Common Stock
-
Pacific Biosciences of California, Inc. Announces Proposed Public Offering of Common Stock
-
Pacific Biosciences of California (PACB) CEO Discusses Departure and Shelf Filing -Cantor Fitzgerald
-
Pacific Biosciences of California (PACB) Management Change Could Be a Fresh Start - Cantor Fitzgerald
-
UPDATE: Cantor Fitzgerald Assumes Pacific Biosciences of California (PACB) at Overweight
-
Cantor Fitzgerald Downgrades Pacific Biosciences of California (PACB) to Neutral
-
Pacific Biosciences of California (PACB) PT Raised to $8 at Cantor Fitzgerald
-
Pacific Bio (PACB) Prices 14.12M Share Common Offering at $4.25/Sh
-
Pacific Biosciences of California, Inc. Announces Pricing of Public Offering of Common Stock
-
Pacific Biosciences of California, Inc. Announces Pricing of Public Offering of Common Stock
-
Pacific Bio (PACB) Proposed Public Offering of Common Stock
-
Pacific Biosciences of California, Inc. Announces Proposed Public Offering of Common Stock
-
Pacific Biosciences of California, Inc. Announces Proposed Public Offering of Common Stock
-
Cantor Fitzgerald Starts Pacific Biosciences of California (PACB) at Overweight
-
Pacific Bio (PACB) Prices 12.5M Share Common Offering at $2.40/Sh
-
Pacific Biosciences of California, Inc. Announces Pricing of Public Offering of Common Stock
-
Pacific Biosciences of California, Inc. Announces Pricing of Public Offering of Common Stock
-
Pacific Bio (PACB) Reports Public Offering of Common Stock
-
Pacific Biosciences of California, Inc. Announces Proposed Public Offering of Common Stock
-
Pacific Biosciences of California, Inc. Announces Proposed Public Offering of Common Stock
-
Pre-Open Movers 06/15: (HTGM) (CTIC) (YTRA) Higher; (KR) (ARNA) (GOOGL) Lower (more...)
-
Pacific Bio (PACB) Prices 15.42M Share Offering at $3.10/Sh
-
Pacific Biosciences of California, Inc. Announces Pricing of Public Offering of Common Stock
-
After-Hours Stock Movers 06/14: (APPS) (ROX) (LAKE) Higher; (PACB) (LNTH) (OAKS) Lower (more...)
-
Pacific Bio (PACB) to Offer Common Stock
-
Pacific Biosciences of California, Inc. Announces Proposed Public Offering of Common Stock
-
Cantor Fitzgerald Reiterates OW Rating and $8 PT on Pacific Biosciences (PACB) Following Solid Results
-
Cantor Fitzgerald Starts Pacific Biosciences of California (PACB) at Buy

